Top Stories
The latest results for the oral small-molecule irreversible EGFR inhibitor come from the Phase III REZILIENT3 study.
The biotech also shared more details on its four-pronged technology platform, which spans target discovery, ultra-high–throughput functional screening, computational binder prediction and optimisation, and AI-enabled safety assessment.
GSK gained Jideytro earlier this year via the purchase of Nuvalent, with the ROS1 selective inhibitor recently winning its first approval.
As part of the rebrand and update to its corporate culture, Novo Nordisk will go by the single 'Novo' name for day-to-day use.
Median overall survival has matured to 18.5 months for gotistobart in the non-pivotal portion of a Phase III study, while remaining at 10 months for standard chemotherapy.
Conference News
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or complete...
New data presented at ACG 2026 demonstrates LANCL2 mechanism targets can reverse expression patterns associated with refractoriness in biologic failure IBD patientsNIM-1324 reduces severity of IBD and...
FirstWord is fielding a poll to 90 US and European pulmonologists to gauge the potential impact of AstraZeneca's tozorakimab for the treatment of chronic obstructive pulmonary disease (COPD), based on newly published Phase III clinical data. We are asking them...
CHENGDU, China, Sept. 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational st...
Longest survival data ever reported in a global Phase III trial in this settingNew data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stagesWILMINGTON, De...
